Skip to content

Study · Non-randomized trial · n = 24 · 1998

5 results

The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities.

Maghnie M, Spica-Russotto V, Cappa M, Autelli M, Tinelli C, Civolani P, Deghenghi R, Severi F, Loche S

The Journal of clinical endocrinology and metabolism1 Nov 1998Cited by 3 (Europe PMC)

PMID9814463 (opens in a new tab)DOI10.1210/jcem.83.11.5242 (opens in a new tab)PepBankPUB-09814463
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In short normal children, the mean peak GH response to hexarelin was higher than that to GHRH.

    In plain wordsIn children with normal short stature, hexarelin gave a higher growth hormone peak than GHRH.

    Peptide
    Hexarelin
    Outcome
    IncreasePeak GH response to hexarelin versus GHRH in short normal children
    Study

    n = 24

    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Measurements

    Peak GH
    48.1 microg/L
    hexarelin
    Peak GH
    24.8 microg/L
    GHRH

    Source sentences

    Summary
    In the short normal children, the mean peak GH response to GHRH (24.8 +/- 4.4 microg/L) was significantly lower than that observed after Hex treatment (48.1 +/- 4.9 microg/L; P < 0.0001).
    2 context sentences
    Summary · context
    We evaluated the GH-releasing effect of hexarelin (Hex; 2 microg/kg, i.v.) and GHRH (1 microg/kg, i.v.) in 18 patients (11 males and 7 females, aged 2.5-20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI).
    Summary · context
    Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within +/-10% of ideal weight) served as controls.
  2. 02HumanNon-randomized trialEfficacy outcome

    In GH-deficient patients, the GH response to hexarelin was significantly higher in those with a residual stalk component than in those without a stalk.

    In plain wordsIn GH-deficient patients, hexarelin gave a higher growth hormone peak when part of the pituitary stalk was present.

    Peptide
    Hexarelin
    Outcome
    IncreasePeak GH response to hexarelin, GHD group 1 versus group 2
    Study

    n = 18

    Comparator
    GHD group 2 (no pituitary stalk)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Measurements

    Peak GH
    7 microg/L
    hexarelin, group 1
    Peak GH
    0.9 microg/L
    hexarelin, group 2

    Source sentences

    Summary
    In the patients of group 1, the GH responses to GHRH (8.7 +/- 1.3 microg/L) and Hex (7.0 +/- 1.3 microg/L) were also similar, but were significantly higher that those observed in group 2 (P < 0.0001).
    3 context sentences
    Summary · context
    In the GHD patients of group 2, the mean peak GH responses to GHRH (1.4 +/- 0.3 microg/L) and Hex (0.9 +/- 0.3 microg/L) were similar and markedly low.
    Summary · context
    We evaluated the GH-releasing effect of hexarelin (Hex; 2 microg/kg, i.v.) and GHRH (1 microg/kg, i.v.) in 18 patients (11 males and 7 females, aged 2.5-20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI).
    Summary · context
    Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within +/-10% of ideal weight) served as controls.
  3. 03HumanNon-randomized trialEfficacy outcome

    In GH-deficient patients, GH peaks after hexarelin correlated significantly with those after GHRH.

    In plain wordsIn GH-deficient patients, those with higher growth hormone peaks after GHRH also tended to have higher peaks after hexarelin.

    Peptide
    Hexarelin
    Outcome
    Not applicableCorrelation of GH peaks after hexarelin and after GHRH
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Measurements

    Correlation coefficient r
    0.746
    Hex vs GHRH GH peaks

    Source sentences

    Summary
    In the whole group of patients, a significant correlation was found between the GH peaks after Hex and those after GHRH (r = 0.746; P < 0.0001).
    2 context sentences
    Summary · context
    We evaluated the GH-releasing effect of hexarelin (Hex; 2 microg/kg, i.v.) and GHRH (1 microg/kg, i.v.) in 18 patients (11 males and 7 females, aged 2.5-20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI).
    Summary · context
    Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within +/-10% of ideal weight) served as controls.
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-deficient patients without a pituitary stalk, the peak GH responses to hexarelin and GHRH were similar and markedly low.

    In plain wordsIn GH-deficient patients without a pituitary stalk, hexarelin and GHRH both gave a very low growth hormone peak.

    Peptide
    Hexarelin
    Outcome
    No significant changePeak GH response to hexarelin versus GHRH in GHD group 2 (no pituitary stalk)
    Study

    n = 10

    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Measurements

    Peak GH
    0.9 microg/L
    hexarelin
    Peak GH
    1.4 microg/L
    GHRH

    Source sentences

    Summary
    In the GHD patients of group 2, the mean peak GH responses to GHRH (1.4 +/- 0.3 microg/L) and Hex (0.9 +/- 0.3 microg/L) were similar and markedly low.
    3 context sentences
    Summary · context
    A residual vascular component of the pituitary stalk was visualized in 8 patients with isolated GHD (group 1), whereas MRI showed the absence of the pituitary stalk (vascular and neural components) in the remaining 10 patients (group 2), of whom 8 had multiple pituitary hormone deficiency and 2 had isolated GHD.
    Summary · context
    We evaluated the GH-releasing effect of hexarelin (Hex; 2 microg/kg, i.v.) and GHRH (1 microg/kg, i.v.) in 18 patients (11 males and 7 females, aged 2.5-20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI).
    Summary · context
    Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within +/-10% of ideal weight) served as controls.
  5. 05HumanNon-randomized trialEfficacy outcome

    In GH-deficient patients with a residual vascular stalk component, the peak GH responses to hexarelin and GHRH were similar.

    In plain wordsIn GH-deficient patients with part of the pituitary stalk, hexarelin and GHRH gave a similar growth hormone peak.

    Peptide
    Hexarelin
    Outcome
    No significant changePeak GH response to hexarelin versus GHRH in GHD group 1 (residual stalk)
    Study

    n = 8

    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 microg/kg · intravenousAs given in this study (human).

    Measurements

    Peak GH
    7 microg/L
    hexarelin
    Peak GH
    8.7 microg/L
    GHRH

    Source sentences

    Summary
    In the patients of group 1, the GH responses to GHRH (8.7 +/- 1.3 microg/L) and Hex (7.0 +/- 1.3 microg/L) were also similar, but were significantly higher that those observed in group 2 (P < 0.0001).
    3 context sentences
    Summary · context
    A residual vascular component of the pituitary stalk was visualized in 8 patients with isolated GHD (group 1), whereas MRI showed the absence of the pituitary stalk (vascular and neural components) in the remaining 10 patients (group 2), of whom 8 had multiple pituitary hormone deficiency and 2 had isolated GHD.
    Summary · context
    We evaluated the GH-releasing effect of hexarelin (Hex; 2 microg/kg, i.v.) and GHRH (1 microg/kg, i.v.) in 18 patients (11 males and 7 females, aged 2.5-20.4 yr) with GH deficiency (GHD) whose hypothalamic pituitary abnormalities had been previously characterized by dynamic magnetic resonance imaging (MRI).
    Summary · context
    Twenty-four prepubertal short normal children (11 boys and 13 girls, aged 5.9-13 yr, body weight within +/-10% of ideal weight) served as controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.